The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Acquired coronary artery aneurysm following treatment with bioresorbable vascular scaffolds

EuroIntervention 2016;12:1174. DOI: 10.4244/EIJV12I9A89

King’s College Hospital NHS Foundation Trust, London, United Kingdom

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

A 41-year-old female underwent deployment of two bioresorbable vascular scaffolds (BVS) (3.5×28 mm, 3.5×18 mm) (Abbott Vascular, Santa Clara, CA, USA) to a long segment of disease in the right coronary artery (RCA) as a staged intervention to bystander disease following a myocardial infarction. Due to a significant waist post deployment, post-dilation with 3.5×20 mm Pantera (Biotronik, Berlin, Germany) and 3.5×12 mm Quantum Apex™ (Boston Scientific, Marlborough, MA, USA) non-compliant balloons to 18 atm was required.

She re-presented with angina 21 months later. Angiography revealed a significant ostial RCA stenosis, with a localised coronary artery aneurysm within the scaffolded segment (Panel A). Pressure wire assessment yielded an FFR of 0.76 with a step at the ostium. Optical coherence tomography confirmed a large, acquired aneurysm at the point of minimal scaffold overlap (Panel B, Panel C). No malapposition was observed, and the scaffold appeared to have expanded with the vessel far beyond normal scaffold dimensions. A short drug-eluting stent (DES) was deployed to the ostium. The aneurysmal segment was managed conservatively with dual antiplatelet therapy (aspirin and clopidogrel).

This extreme form of positive remodelling in a BVS has not, to our knowledge, been described previously. The mechanism of acquired aneurysm following DES/BVS deployment remains unclear; however, hypersensitivity to the drug and/or polymer is possible. In this case, it is possible that “double-dose” everolimus at the point of BVS overlap may have been a factor in aneurysm formation.

Conflict of interest statement

J. Hill has received consulting fees from Abbott and St. Jude Medical. The other authors have no conflicts of interest to declare.

Read next article

An unexpected huge coronary aneurysm